Monitor for any definitive announcement regarding a Velocity Bioworks sale or partnership, which could unlock value. Also watch for clinical trial updates on Entolimod's GI radiation injury program and oral mucosal formulation.
Price Chart
Executive Summary
Valion Bio's interim CEO Dean Zikria released a 30-day strategic review outlining three priorities: advancing the Entolimod pipeline, commercializing the Velocity Bioworks CDMO, and evaluating strategic transactions for Velocity (including a potential sale). The filing is a non-financial strategic update with no new financial data, clinical results, or definitive transaction commitments.
Key Facts
- Interim CEO Dean Zikria completed a 30-day strategic review and set a three-priority agenda
- Entolimod has received approximately $35.6 million in non-dilutive U.S. government funding to date
- Velocity Bioworks CDMO is being evaluated for strategic partnerships, co-investment, licensing, or a sale
- No definitive transaction has been committed to for Velocity
- Entolimod holds FDA Fast Track and Orphan Drug designations for Acute Radiation Syndrome (ARS)
- Company is pursuing an oral mucosal formulation of Entolimod with Shear Kershman Laboratories
- Entolasta, a next-generation TLR5 agonist, is being advanced for oncology supportive care
Financial Impact
No financial figures reported beyond the $35.6 million in historical non-dilutive government funding for Entolimod. No revenue, earnings, or guidance provided.
Risk Factors
- No guarantee that the strategic review of Velocity will result in any transaction
- Entolimod remains a clinical-stage asset with no approved product and uncertain regulatory path under the FDA Animal Rule
- Company's ability to fund pipeline advancement without additional capital is unclear from this filing
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-033175 |
| Exhibit: ex_1029316.htm | 0001437749-26-033175 |
| Document: 0001437749-26-033175-index-headers.html | 0001437749-26-033175 |
| Document: 0001437749-26-033175-index.html | 0001437749-26-033175 |
| Document: 0001437749-26-033175.txt | 0001437749-26-033175 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.8950 | awaiting T+20 | — | $0.7820 (+12.63%) |
Oct 26, 2026 1d ago | 8-K | $0.8400 | awaiting T+20 | — | $0.7820 (−6.90%) |
Oct 22, 2026 5d ago | 8-K | $0.9560 | awaiting T+20 | — | $0.7820 (−18.20%) |
Oct 21, 2026 7d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.7820 (+30.18%) |
Oct 21, 2026 7d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.7820 (+30.18%) |
Oct 16, 2026 11d ago | S-3 | $1.16 | awaiting T+20 | — | $0.7820 (+32.59%) |
Oct 16, 2026 11d ago | DEF 14A | $1.16 | awaiting T+20 | — | $0.7820 (+32.59%) |
Oct 15, 2026 12d ago | 8-K | $1.23 | awaiting T+20 | — | $0.7820 (−36.42%) |
Oct 14, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $0.7820 (−46.07%) |
Oct 8, 2026 19d ago | 8-K | $2.21 | awaiting T+20 | — | $0.7820 (+64.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers